Moxidectin elevates Candida albicans ergosterol levels to synergize with polyenes against oral candidiasis.

ABSTRACT: Candida albicans, the most common opportunistic pathogenic fungus, is also the main pathogenic organism for oral candidiasis. This condition is particularly prevalent among the elderly, children, and individuals undergoing radiotherapy or suffering from HIV. The lack of new antifungal drugs, and drug resistance coupled with the side effects of current antifungal agents have increased the challenges of clinical antifungal therapies. Polyenes, including amphotericin B and nystatin, are clinical fungicidal drugs, however, their side effects and low solubility have limited their clinical applications. Here, we identified that moxidectin, a novel approved antiparasitic agent, could synergize with both amphotericin B and nystatin to inhibit the growth and biofilm formation of Candida albicans in

SUBMITTER: Ye X 

PROVIDER: S-EPMC11554702 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature